Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFα and IL18 but not CXCL12
Open Access
- 1 April 2005
- journal article
- clinical trial
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 64 (4) , 537-543
- https://doi.org/10.1136/ard.2004.024927
Abstract
Background: Tumour necrosis α (TNFα) blocking agents lead to pronounced clinical effects and reduced synovial infiltrate in rheumatoid arthritis. Laboratory and clinical studies suggest that TNFα independent pathways play a role in the disease. Objectives: To evaluate the immunopathological effects of combination therapy on rheumatoid synovial tissue in order to identify TNFα independent mechanisms. Methods: 12 rheumatoid patients, including four DMARD (disease modifying antirheumatic drug) naive patients with early disease, were studied for the effect of combination therapy with infliximab and methotrexate on the synovial infiltrate. Biopsies and clinical assessments (DAS28) were carried out before the first and after the third infusion of infliximab. Synovial inflammation was scored semiquantitatively. Co-expression of CD38+ cells was studied by an immunofluorescent double labelling technique. Results: Marked clinical responses were associated with a global reduction in the synovial infiltrate and expression of cytokines, notably interleukin 18 and TNFα, but low grade disease activity persisted. There was no effect on the expression of CXC chemokine ligand (CXCL12), and germinal centre-like structures were still detectable in synovial tissue in two patients after treatment. CD38+ activated T cells were more resistant to treatment than CD38+ plasma cells. No differences in clinical response or effects on synovial infiltrate were observed between DMARD refractory and DMARD naive patients. Conclusions: Persistent expression of CXCL12 and incomplete resolution of lymphocytic infiltrates after infliximab plus methotrexate indicates that TNFα independent mechanisms are operative in rheumatoid arthritis. This may contribute to low grade disease activity, even in DMARD naive patients with early disease.Keywords
This publication has 29 references indexed in Scilit:
- Hypoxia‐induced production of stromal cell–derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblastsArthritis & Rheumatism, 2002
- Anti-tumour necrosis factor (TNF) α treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13Annals of the Rheumatic Diseases, 2002
- Stromal cell–derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID MiceArthritis & Rheumatism, 2002
- Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritisArthritis & Rheumatism, 2000
- Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells.Journal of Clinical Investigation, 1998
- A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1British Journal of Haematology, 1996
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988